Novel drugs targeting the cell cycle

Expert Opinion on Emerging Drugs

Volumn 5, Issue 1, 2000, Pages 45-59

  Webster, Kevin R ^a   Kimball, S David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

cancer; cdk; cell cycle; chemotherapy; cyclin dependent kinase; flavopiridol

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; 7 HYDROXYSTAUROSPORINE; AG 12275; ALSTERPAULLONE; BICALUTAMIDE; CARBOPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; ENZYME INHIBITOR; EPIRUBICIN; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; GOSERELIN; IRINOTECAN; LETROZOLE; LEUPRORELIN; N METHYL 4 [2 (2 OXOPYRIDO[2,3 E]INDOL 3 YLIDENE)HYDRAZINO]PHENYLMETHANESULFONAMIDE; NAVELBINE; OLOMOUCINE; PACLITAXEL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STAUROSPORINE; TAMOXIFEN CITRATE; TOPOTECAN; UNCLASSIFIED DRUG;

CELL CYCLE; HUMAN; REVIEW;

EID: 0033995530     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.1.45     Document Type: Review

References (60)

1. NASMYTHK: Viewpoint: putting the cell cycle in order. Science (1996) 274(5293):1643-1645.
2. HARTWELL LH, WEINERT TA: Checkpoints: controls that ensure the order of cell cycle events. Science (1989) 246(4930):629-634.
3. ELLEDGE SJ: Cell cycle checkpoints: preventing an identity crisis. Science (1996) 274(5293):1664-1672.
4. PAULOVICH AG, TOCZYSKI DP, HARTWELL LH: When checkpoints fail. Cell (1997) 88(3):315-321.
5. PARDEE AB: A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA (1974) 71(4):1286-1290.
6. CONNELL-CROWLEY L, ELLEDGE SJ, HARPER JW: G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr. Biol. (1998) 8(1):65-68.
7. PISANI P, PARKIN DM, BRAY F, FERLAY J: Estimates of the worldwide mortality from25cancersin1990. Int. J. Cancer (1999) 83(1):18-29.
8. PEGRAM MD, SLAMON DJ: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol. (1999) 26(4 Suppl. 12):89-95.
9. Cancer therapy sales to double. Med. Adv. News (1999):42-50.
10. HANKS SK, QUINN AM, HUNTER T: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 241(4861):42-52.
11. CZECH J, HOFFMANN D, NAIK R, SEDLACEK H-H: Antitu-moral activity of flavone L86-8275. Int. J. Oncol. (1995) 6:31-36.
12. DREES M, DENGLER WA, ROTH T et al.: Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. (1997) 3:273-279.
13. BIBLE KC, KAUFMANN SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. (1997) 57:3375-3380
14. SCHWARTZ GK, FARSIK,MASLAKP, KELSEN DP, SPRIGGS D: Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res. (1997) 3:1467-1472.
15. ONGKEKO W, FERGUSON DJ, HARRIS AL, NORBURY C: Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. (1995) 108(Pt 8):2897-2904.
16. MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131-134.
17. GOULD KL: Cyclin-dependent protein kinases. In: Protein Kinases. Woodgett JR (Ed.), Oxford University Press, Oxford, UK (1994):149-166.
18. VAN DEN HEUVEL S, HARLOW E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science (1993) 262(5142):2050-2054.
19. NIGG EA: Cellular substrates of p34cdc2 and its companion cyclin-dependent kinases. Trends Cell Biol. (1993) 3:296-301.
20. RICKERT P, SEGHEZZI W, SHANAHAN F, CHO H, LEES E: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 12(12):2631-2640.
21. DYNLACHT BD, MOBERG K, LEES JA, HARLOW E, ZHU L: Specific regulation of E2F family members by cyclin-dependent kinases. Mol. Cell Biol. (1997) 17(7):3867-3875.
22. OOKATA K, HISANAGA S, SUGITA M et al.: MAP4 is the in vivosubstrate for CDC2 kinase inHeLa cells: identification of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4. Biochemistry (1997) 36(50):15873-15883.
23. PINES J, HUNTER T: Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell (1989) 58:833-846.
24. KING RW, DESHAIES RJ, PETERS JM, KIRSCHNER MW: How proteolysis drives the cell cycle. Science (1996) 274(5293):1652-1659.
25. PAGANO M: Cell cycle regulation by the ubiquitin pathway. Faseb J. (1997) 11(13):1067-1075.
26. LI J, MEYER AN, DONOGHUE DJ: Nuclear localization of cyclin B1 mediates its biological activity and is regulated byphosphorylation. Proc. Natl. Acad. Sci. USA (1997) 94(2):502-507.
27. DRAETT AG, BEACH D: Activation of cdc2 protein kinase during mitosis in human cells: cell-cycle-dependent phosphorylation and subunit rearrangement. Cell (1988) 54:17-26.
28. HARPER JW: Cyclin dependent kinase inhibitors. Cancer Surv. (1997) 29:91-107.
29. NAIK RG, KATTIGE SL, BHAT SV: An antiinflammatory cum immunomodulatory properidinylbenzopy-ranone from Dysoxylum binectariferum: isolation structure, and total synthesis. Tetrahedron (1988) 44:2081-2086.
30. KAUR G, STETLER-STEVENSON M, SEBERS Setal.: Growth inhibition with reversible cell cycle arrest of carcinoma cellsbyflavone L86-8275. J. Natl. Cancer Inst. (1992) 84(22):1736-1740.
31. LOSIEWICZ MD, CARLSON BA, KAUR G, SAUSVILLE EA, WORLAND PJ: Potent inhibitionofCDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. (1994) 201(2):589-595.
32. CARLSON BA, DUBAY MM, SAUSVILLE EA, BRIZUELA L, WORLAND PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. (1996) 56(13):2973-2978.
33. SHAPIRO GI, KOESTNER DA, MATRANGA CB, ROLLINS BJ: Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. (1999) 5(10):2925-2938.
34. SEDLACEK HH: Flavopiridol (L868275: NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. (1996) 9:1143-1168.
35. SENDEROWICZ AM, HEADLEE D, STINSON SFetal.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. (1998) 16(9):2986-2999.
36. SHAPIRO G, PATTERSON A, LYNCH C et al.: A Phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1999).Atlanta, GA, USA.
37. BENNET P, MANI S, O'REILLY S et al.: Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results. Proc. Am. Soc. Clin. Oncol. (1999) Atlanta, GA, USA.
38. WEBSTER KR, MULHERON JG, QIAN L et al.: Thio-flavopiridol, a selective inhibitor of cdk1. Proc. Am. Assoc. Cancer Res. Philadelphia, PA, USA (1999).
39. DE AZEVEDO WF, LECLERC S, MEIJER L et al.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. (1997) 243(1-2):518-526.
40. MGBONYEBI OP, RUSSO J, RUSSO IH: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. (1999) 59(8):1903-1910.
41. GRAY NS, WODICKA L, THUNNISSEN AM et al.: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 281(5376):533-538.
42. IMBACH P, CAPRARO HG, FURET P et al.: 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. (1999) 9(1):91-96.
43. NUGIEL DA, CORNELIUS LAM, CORBETT JW, JEFFREY W: Facile preparation of 2,6-disubstituted purines using solid-phase chemistry. J. Org. Chem. (1997) 62(1):201-203.
44. OH CH, LEE SC, LEE KS et al.: Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor. Arch Pharm. (Weinheim) (1999) 332(6):187-190.
45. NORMAN TC, GRAY NS, KOH JT, SCHULTZ PG: A structure-based library approach to kinase inhibitors. J. Am. Chem. Soc. (1996) 118:7430-7431.
46. ZIMMERMANN J, BUCHDUNGER E, FABBRO E et al.: Phenylamino-pyrimidines: a new class of highly selective protein kinase inhibitors. 1st Italian-Swiss Meeting on Medicinal Chem. Turin, Italy (1997).
47. PRADE L, ENGH RA, GIROD A et al.: Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure (1997) 5(12):1627-1637.
48. FAHRAEUS R, PARAMIO JM, BALL KL, LAIN S,LANE DP: Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol. (1996) 6(1):84-91.
49. CHEN YN, SHARMA SK, RAMSEY TM et al.: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA. (1999) 96(8):4325-4329.
50. WEBSTER KR: The therapeutic potential of targeting the cell cycle. Exp. Opin. Invest. Drugs (1998) 7(6):865-887.
51. VESELY J, HAVLICEK L, STRNAD M et al.: Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. (1994) 224:771-786.
52. HAVLICEK L, HANUS J, VESELY J et al.: Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. (1997) 40(4):408-412.
53. BROOKS EE, GRAY NS, JOLY A et al.: CVT-313, a specific and potentinhibitorofCDK2 that prevents neointimal proliferation. J. Biol. Chem. (1997) 272(46):29207-29211.
54. RUETZ ST, WOODS-COOK K, SOLF R et al.: Effect of CGP 60474 on cyclin dependent kinases (cdks), cell cycle progression and onset of apoptosis in normal and transformed cells. Proc. Am. Assoc. Cancer Res. New Orleans, LA, USA (1998).
55. LI L, DUVADIE RK, CHONG WKM et al.: Novel ATP-site cyclin-dependent kinase (cdk) inhibitors. Selective inhibitors of cdk4. ACS. (1999).
56. DUVADIE RK, LI L, CHONG WKM et al.: Novel ATP-site cyclin-dependent kinase (cdk) inhibitors. Selective cdk inhibitors. In: ACS. (1999).
57. WALKER DH, LUZZIO M, VEAL J et al.: The novel cyclin-dependent kinase inhibitors, GW5181 and GW9499 regulate cell cycle progression and induce tumor-selective cell death. Proc. Am. Assoc. Cancer Res. Philadelphia, PA, USA (1999).
58. SCHULTZ C, LINK A, LEOST Met al.: Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. (1999) 42(15):2909-2919.
59. KAWAKAMI K, FUTAMI H, TAKAHARA J, YAMAGUCHI K: UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun. (1996) 219(3):778-783.
60. GESCHER A: Analogs of staurosporine: potential anticancerdrugs? Gen. Pharmacol. (1998) 31(5):721-728.